Working to Improve the
Management of ITP!
Idiopathic thrombocytopenic purpura (ITP) is an autoimmune disorder characterized by very low platelet counts and a resulting risk of severe bleeding complications. Primary, immune-mediated ITP is treated with therapies ranging from splenectomy to intravenous immunoglobulin, treatments for which the risks sometimes outweigh the benefits. ITP can also occur secondary to other disorders, including HIV infection, chronic hepatitis C infection, myelodysplastic syndromes, and as a consequence of cancer chemotherapy.
There are currently limited therapeutic options for the management of ITP and often these may be inappropriate for some patients with ITP. However, there are new therapies for ITP on the horizon, and it is important that clinicians are kept informed on the latest clinical trial results. This education will help hematologists, oncologists, and other health care professionals managing patients with ITP and related thrombocytopenic complications in the areas of diagnosis and management of ITP in a wide variety of clinical situations.
New – Expert On Call
Michael D. Tarantino, MD
Please submit a question by clicking the link below. Response to questions will be answered the following Friday.
Each month, an expert in ITP will be "On Call" to answer your ITP-related questions. Check back each month for updates!
